The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 | MicrobiomeTrials← Back to trialsNCT05085561
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2022-03-17Est. Completion: 2025-06-30
Enrollment target: 62 participants Locations- Xenoscience Inc, Phoenix, Arizona, United States
- UCLA, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- University of Florida, Gainesville, Florida, United States
- Lyerly Neurosurgery, Jacksonville, Florida, United States
- Cleveland Clinic Florida, Port Saint Lucie, Florida, United States
- Emory, Atlanta, Georgia, United States
- Valley Hospital, Ridgewood, New Jersey, United States
- Columbia University Medical Center, New York, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- The University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Virginia, Charlottesville, Virginia, United States
Other microbiome trials you might be interested in
Cavernous Angioma, FamilialCerebral Cavernous MalformationsCerebral Cavernous Hemangioma
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed an…
Phoenix, United StatesCompleted Mar 31, 2025
CADASILCavernous AngiomaCerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and LeukoencephalopathySmall Vessel Disease
CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry…
Multiple LocationsEst. completion Jun 30, 2038